文献速递肝病

直接抗病毒治疗期间丙型肝炎病毒血症清除导致血脂和脂蛋白代谢快速变化

Clearance of Hepatitis C Viremia During Direct-Acting Antiviral Therapy Leads to Rapid Changes in Lipid and Lipoprotein Metabolism.
PubMed 文献 · Aliment Pharmacol Ther · 2025-05-13

本研究回顾性分析60例基因1-4型初治丙型肝炎患者接受12周索磷布韦-维帕他韦治疗,发现病毒血症下降伴随总胆固醇、HDL-C、LDL-C、载脂蛋白A-1和B及GlycA快速显著升高,ALT、肝脏炎症和脂肪变性改善,但血糖控制无变化;治疗结束后第24周ASCVD和Framingham风险评分显著升高。

要点

  • 丙型肝炎病毒血症下降与总胆固醇、HDL-C、LDL-C、ApoA-1、ApoB和GlycA快速显著升高相关。
  • 病毒清除伴随ALT、肝脏炎症和脂肪变性改善,但HOMA-IR和HbA1c无变化。
  • 治疗结束后第24周ASCVD和Framingham风险评分显著升高,但需前瞻性研究验证。

核心结论

  • 直接抗病毒治疗抑制病毒复制期间血脂和脂蛋白快速升高,该效应可能由影响肝脏从头脂肪生成的基因介导。
  • 基于血脂变化,丙型肝炎病毒清除可能增加心血管疾病风险,但需前瞻性研究验证。

研究设计与样本

  • 回顾性分析60例初治基因1-4型丙型肝炎患者接受12周索磷布韦-维帕他韦治疗的储存血清和血浆。
  • 系列检测血清血脂、载脂蛋白和GlycA,并对血浆样本进行NMR LipoProfile分析。
  • 评估治疗前和治疗中配对肝活检中脂质代谢调节基因的表达。
  • 使用线性混合模型分析血脂和炎症标志物变化,并评估治疗前后Framingham和ASCVD心血管疾病风险评分。

主要发现

  • 丙型肝炎病毒血症下降与总胆固醇、HDL-C、LDL-C、ApoA-1、ApoB和GlycA快速显著升高相关。
  • ALT、肝脏炎症和脂肪变性改善,但血糖控制(HOMA-IR和HbA1c)无变化。
  • 总胆固醇、LDL-C和ApoB升高与SREBP1表达增加相关。
  • 调整年龄后,治疗结束后第24周ASCVD和Framingham风险评分均显著升高(p < 0.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Chronic hepatitis C virus (HCV) infection is associated with hypolipidemia. HCV eradication may, therefore, result in hyperlipidemia and increase cardiovascular disease (CVD) risk. We investigated the impact of HCV eradication on serum lipid and lipoprotein profiles and CVD risk during and following direct-acting antiviral (DAA) therapy. APPROACH AND RESULTS: We retrospectively analysed stored sera and plasma from 60 DAA-naïve patients, genotypes 1-4, treated with 12 weeks of sofosbuvir-velpatasvir. Serum lipids, apolipoproteins (apo), and a systemic inflammatory marker, GlycA, were measured serially beginning early on treatment and off treatment. Additionally, NMR LipoProfile analysis was performed on plasma samples. Expression of genes regulating lipid metabolism was assessed from paired liver biopsies obtained before and on treatment. Linear mixed models were used to examine changes in lipid and inflammatory markers; Framingham and ASCVD CVD risk scores were assessed before and after treatment. Decline in HCV viremia was associated with a rapid, significant increase in TChol, HDL-C, LDL-C, ApoA-1 and ApoB, and GlycA, improvement in ALT, hepatic inflammation, and steatosis but no change in glycemic control (HOMA-IR and HbA1c). Increase in TChol, LDL-C, and ApoB was associated with an increased SREBP1expression. Both ASCVD and Framingham risk scores were significantly increased at week 24 post treatment after adjusting for age (p < 0.0001). CONCLUSION: Serum lipids and lipoproteins rapidly increase with inhibition of viral replication during DAA therapy, an effect that may be mediated by genes affecting hepatic de novo lipogenesis. Based on lipid changes, HCV eradication may increase CVD risk, but this needs to be investigated prospectively.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Sarrafan-Chaharsoughi Z, Takyar V, Auh S, et al. Clearance of Hepatitis C Viremia During Direct-Acting Antiviral Therapy Leads to Rapid Changes in Lipid and Lipoprotein Metabolism. Aliment Pharmacol Ther. 2025. PMID: 40364525. doi:10.1111/apt.70130

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。